** Inovio Pharmaceuticals' INO.O shares down 33% premarket to $1.43 after follow-on prices
** Plymouth Meeting, Pennsylvania-based firm announces ~14.3 mln shares along with warrants to buy additional 14.3 mln shares at $1.75 for $25 mln gross proceeds
** Offering price represents 18.2% discount to stock's last close
** It intends to use net proceeds primarily for development of clinical pipeline, preparing for a potential commercial launch of INO-3107, if approved, and for general purposes, per the prospectus
** INO-3107 is a potential treatment for recurrent respiratory papillomatosis, a benign tumor disease
** With ~36.7 mln shares outstanding, co has about $78 mln market cap through Weds
** INO shares on Weds ended up 4.9%, up 17% YTD
** Piper Sandler sole active bookrunner for the offering, joined by Oppenheimer
** Avg rating among 5 analysts is "buy" and median PT is $10, LSEG data reflects
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。